Exiqon Q1 Revenues Improve 33 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Danish genomics and molecular diagnostics company Exiqon said today that revenues in the first quarter rose 33 percent year over year on the strength of its research products.

For the three months ended March 31, the company took in DKK31.8 million ($5.6 million) in revenues, up from DKK24.0 million a year ago. Research product sales and services, excluding original equipment manufacturing revenues, increased 34 percent to DKK25.7 million, with business in Europe and the rest of the world driving revenue growth, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.